What is the recommended dose and administration schedule of Flumist (live‑attenuated influenza vaccine)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 4, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

FluMist Dosing Recommendations

FluMist is administered as a single 0.2 mL intranasal dose (0.1 mL per nostril) for persons aged 9-49 years, while children aged 2-8 years require either one or two doses depending on their prior influenza vaccination history. 1

Dosing by Age Group

Children 2-8 Years Old

  • Two doses (0.2 mL each): Required for children who have never received any influenza vaccine (either LAIV or inactivated vaccine)

    • Doses must be separated by at least 1 month (4 weeks minimum) 1
    • Older ACIP guidance specified 6-10 weeks between doses 2, but current FDA labeling indicates at least 1 month 1
  • One dose (0.2 mL): Sufficient for children previously vaccinated with any influenza vaccine 2, 1

Persons 9-49 Years Old

  • One dose (0.2 mL) administered annually 2, 1

Administration Technique

Each single-dose sprayer contains 0.2 mL total volume:

  • Administer approximately 0.1 mL into each nostril (half the dose per nostril) 1
  • Patient should be in upright position 2
  • A dose-divider clip on the sprayer is removed after the first nostril to deliver the second half 2
  • If the patient sneezes after administration, do NOT repeat the dose 2

Critical Contraindications and Precautions

Do not administer FluMist to:

  • Children and adolescents (through age 17) receiving aspirin or aspirin-containing therapy due to Reye's syndrome risk 1
  • Children younger than 2 years (increased risk of hospitalization and wheezing) 1
  • Persons younger than 2 years or 50 years and older 2
  • Persons with asthma, reactive airways disease, or chronic cardiopulmonary disorders 2
  • Immunocompromised individuals 2
  • Pregnant women 2
  • Those with severe egg allergy or anaphylaxis to vaccine components 1

Timing Considerations

  • Optimal vaccination period: October through November 2
  • Children 2-8 years requiring two doses should start in October or earlier to allow time for the second dose 2
  • Can defer if significant nasal congestion is present that would impede vaccine delivery 2
  • Antiviral medication interactions:
    • Wait 48 hours after stopping influenza antivirals before giving FluMist 2
    • Avoid influenza antivirals for 2 weeks after FluMist administration 2

Key Clinical Pearls

The two-dose requirement for vaccine-naive young children is critical—this population needs both a priming dose and booster to mount adequate protective antibody responses 3. Missing the second dose leaves these children inadequately protected. The distinction between "previously vaccinated" (one dose needed) versus "never vaccinated" (two doses needed) applies to any prior influenza vaccination history, whether with LAIV or inactivated vaccine 2, 1.

Children aged 2-17 years should not self-administer FluMist; it must be given by a healthcare provider or caregiver 1.

References

Research

Seasonal influenza vaccines.

Current topics in microbiology and immunology, 2009

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.